Aurlumyn is a prescription medication used to treat moderate to severe atopic dermatitis in adults and children aged 12 and older [1]. It is administered as a subcutaneous injection [1]. The drug is marketed by Sanofi and Regeneron Pharmaceuticals [2].
How is Aurlumyn administered?
Aurlumyn is given as a self-injection under the skin [1]. The initial dosage involves specific injection schedules, followed by maintenance doses [1]. Patients are trained on how to administer the injection themselves [1].
What is Aurlumyn used for?
Aurlumyn treats moderate to severe atopic dermatitis, also known as eczema, in individuals aged 12 and above who are candidates for systemic therapy or phototherapy [1]. It works by targeting specific inflammatory pathways involved in the condition [1].
How does Aurlumyn compare to other eczema treatments?
Aurlumyn, a biologic medication, targets specific immune system pathways, unlike topical treatments that act directly on the skin [3]. It is a potential alternative for patients whose atopic dermatitis is not adequately controlled by other therapies [3]. The efficacy and safety profile of Aurlumyn are evaluated in clinical trials against existing treatment standards [1].
What are the potential side effects of Aurlumyn?
Common side effects reported with Aurlumyn include upper respiratory infections, injection site reactions, fever, headache, and diarrhea [1]. More serious, though less common, side effects can include allergic reactions and infections [1]. Patients are advised to report any new or worsening symptoms to their healthcare provider [1].
When was Aurlumyn approved?
Aurlumyn received approval from the U.S. Food and Drug Administration (FDA) in December 2023 [2].
Who manufactures Aurlumyn?
Aurlumyn is developed and marketed by Sanofi and Regeneron Pharmaceuticals through their ongoing collaboration [2].
What is the prescribing information for Aurlumyn?
The prescribing information for Aurlumyn details its indication, dosage, administration, contraindications, warnings, precautions, adverse reactions, and clinical trial data [1]. It is available through the FDA's website and medical information portals [1].
Where can I find more information about Aurlumyn?
More detailed information about Aurlumyn, including its clinical studies, patient information, and prescribing details, can be found on the FDA's official website and through Sanofi and Regeneron's medical information resources [1][2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/219105s000lbl.pdf
[2] https://www.sanofi.us/en/media-room/press-releases/2023/sanofi-and-regeneron-announce-fda-approval-of-aurlumyn-dupilumab-for-atopic-dermatitis
[3] https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-episode-14-new-drug-approval-aurlumyn-dupilumab